Sequencing in Focus: Pharmacists Reflect on the Impacts of MajesTEC-3 and MajesTEC-9 Data in Myeloma

In this episode, 'Sequencing in Focus: Pharmacists Reflect on the Impacts of MajesTEC-3 and MajesTEC-9 Data in Myeloma,' the oncology pharmacists explore the following questions:

How has the tec-dara prior exposure data shaped how you think about sequencing, and what does that data show for patients with prior exposure?

Now with the latest MajesTEC-9 data studying teclistamab monotherapy, what are your impressions of that data?

The panelists examined the landmark MajesTEC-3 data, highlighting the striking hazard ratio of 0.17 for progression-free survival with the teclistamab plus daratumumab combination versus investigator's choice of daratumumab-based triplet therapy, as well as a statistically significant overall survival benefit at 34.5 months of follow-up, establishing the TecDara combination as an FDA-approved and NCCN-incorporated second-line standard for appropriate patients. The discussion also contextualized an important limitation of the MajesTEC-3 data, that only approximately 5% of trial patients had received prior daratumumab, reflecting the enrollment period before quadruplet induction became standard, and highlighted the MajesTEC-9 trial presented at ASCO as a critical next step, showing that teclistamab monotherapy significantly outperformed investigator's choice triplet and doublet regimens even in a population that was approximately 85% daratumumab-refractory. The panelists closed with an optimistic forward-looking perspective on sequencing, anticipating that maturing data for elranatamab and linvoseltamab will similarly support earlier-line use, and expressing excitement about the possibility of time-limited bispecific therapy protocols in the future, where patients might complete a defined course of treatment and achieve durable responses without remaining on therapy indefinitely.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Outpatient Bispecific Initiation: Emerging Trends, Eligibility Criteria, and Operational Readiness,' features the panelists advancing their conversation on multiple myeloma and focusing on the growing trend toward outpatient bispecific antibody initiation.